The clinicopathological and prognostic relevance of pyruvate kinase M2 and pAkt expression in breast cancer

Anticancer Research

Volumn 30, Issue 5, 2010, Pages 1689-1694

  Benesch, Carina ^a   Schneider, Christine ^a   Voelker, Hans Ullrich ^a   Kapp, Michaela ^a   Caffier, Hans ^a   Krockenberger, Mathias ^a   Dietl, Johannes ^a   Kammerer, Ulrike ^a   Schmidt, Melanie ^a  

^a UNIVERSITY OF WÜRZBURG   (Germany)

Author keywords

Breast cancer; M2PK; PAkt; Tumour glycolysis

Indexed keywords

PROTEIN KINASE B; PYRUVATE KINASE; PYRUVATE KINASE M2; UNCLASSIFIED DRUG;

ADULT; AGED; BREAST CANCER; CANCER SURVIVAL; CONFERENCE PAPER; CONTROLLED STUDY; ENZYME ANALYSIS; GLYCOLYSIS; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION;

ADULT; AGED; BREAST NEOPLASMS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GLUCOSE; HUMANS; MIDDLE AGED; NEOPLASM METASTASIS; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-AKT; PYRUVATE KINASE; RECEPTORS, ESTROGEN; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 77954569372     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (22)

1. Stabenow R: Vortrag Deutsche Gesellschaft für Senologie. GKR Berlin, 2003.
2. Singletary SE and Connolly JL: Breast cancer staging: working with the sixth edition of the AJCC Cancer Staging Manual. CA Cancer J Clin 56: 37-47, 2006.
3. Warburg O: Über den Stoffwechsel der Carcinomzelle. Die Naturwissenschaften 50: 1131-1137, 1924.
4. Dang CV and Semenza GL: Oncogenic alterations of metabolism. Trends Biochem Sci 24: 68-72, 1999.
5. Elstrom RL, Bauer DE, Buzzai M, Karnauskas R, Harris MH, Plas DR, Zhuang H, Cinalli RM, Alavi A, Rudin CM and Thompson CB: Akt stimulates aerobic glycolysis in cancer cells. Cancer Res 64: 3892-3899, 2004.
6. Shim H, Chun YS, Lewis BC and Dang CV: A unique glucose-dependent apoptotic pathway induced by c-Myc. Proc Natl Acad Sci USA 95: 1511-1516, 1998.
7. Ramanathan A, Wang C and Schreiber SL: Perturbational profiling of a cell-line model of tumorigenesis by using metabolic measurements. Proc Natl Acad Sci USA 102: 5992-5997, 2005.
8. Gumińska M, Ignacak J, Kedryna T and Stachurska MB: Tumor-specific pyruvate kinase isoenzyme M2 involved in biochemical strategy of energy generation in neoplastic cells. Acta Biochim Pol 44: 711-724, 1997.
9. Mazurek S, Boschek CB, Hugo F and Eigenbrodt E: Pyruvate kinase type M2 and its role in tumor growth and spreading. Semin Cancer Biol 15: 300-308, 2005.
10. Schmidt M, Kammerer U, Segerer S, Cramer A, Kohrenhagen N, Dietl J and Voelker HU: Glucose metabolism and angiogenesis in granulosa cell tumors of the ovary: activation of Akt, expression of M2PK, TKTL1 and VEGF. Eur J Obstet Gynecol Reprod Biol 139: 72-78, 2008.
11. Schmidt M, Voelker HU, Kapp M, Krockenberger M, Dietl J and Kammerer U: Glycolytic phenotype in breast cancer: activation of Akt, up-regulation of GLUT1, TKTL1 and down-regulation of M2PK. J Cancer Res Clin Oncol 136: 219-225, 2010.
12. Sun M, Wang G, Paciga JE, Feldman RI, Yuan ZQ, Ma XL, Shelley SA, Jove R, Tsichlis PN, Nicosia SV and Cheng JQ: AKT1/PKBalpha kinase is frequently elevated in human cancers and its constitutive activation is required for oncogenic transformation in N1H3T3 cells. Am J Pathol 159: 431-437, 2001.
13. Barnes K, Mcintosh E, Whetton AD, Daley GQ, Bentley J and Baldwin SA: Chronic myeloid leukaemia: an investigation into the role of Bcr-Abl-induced abnormalities in glucose transport regulation. Oncogene 24:3257-3267, 2005.
14. Rathmell JC, Fox CJ, Plas DR, Hammerman PS, Cinalli RM and Thompson CB: Akt-directed glucose metabolism can prevent Bax conformation change and promote growth factor-independent survival. Mol Cell Biol 23: 7315-7328, 2003.
15. Buzzai M, Bauer DE, Jones RG, Deberardinis RJ, Hatzivassiliou G, Elstrom RL and Thompson CB: The glucose dependence of Akt-transformed cells can be reversed by pharmacologic activation of fatty acid beta-oxidation. Oncogene 24: 4165-4173, 2005.
16. Majewski N, Nogueira V, Bhaskar P, Coy PE, Skeen JE, Gottlob K, Chandel NS, Thompson CB, Robey RB and Hay N: Hexokinase-mitochondria interaction mediated by Akt is required to inhibit apoptosis in the presence of Bax and Bak. Mol Cell 16: 819-830, 2004.
17. Godoy A, Ulloa V, Rodriguez F, Reincke K, Yanez AJ, Garcia MDLA, Medina RA, Carrasco M, Barberis S, Castro T, Martinez F, Koch X, Vera JC, Poblete MT, Figueroa CD, Peruzzo B, Perez F and Nualart F: Differential subcellular distribution of glucose transporters GLUT1-6 and GLUT9 in human cancer: Ultrastructural localization of GLUTI and GLUT5 in breast tumor tisues. J Cell Physiol 207: 614-627, 2006.
18. Robey RB and Hay N: Mitochondrial hexokinases, novel mediators of the antiapoptotic effects of growth factors and Akt. Oncogene 25: 4683-4696, 2006.
19. Bauer DE, Hatzivassiliou G, Zhao F, Andreadis C and Thompson CB: ATP citrate lyase is an important component of cell growth and transformation. Oncogene 24: 6314-6322, 2005. (Pubitemid 43080054)
20. Schneider J, Neu K, Velcovsky HG, Morr H and Eigenbrodt E: Tumor M2-pyruvate kinase in the follow-up of inoperable lung cancer patients: a pilot study. Cancer Lett 193: 91-98, 2003.
21. Remmele W and Stegner HE: Recommendation for uniform definition of an immunoreactive score (1RS) for immunohistochemical estrogen receptor detection (ER-ICA) in breast cancer tissue. Pathologe 8: 138-140, 1987.
22. Young CD and Anderson SM: Sugar and fat - that's where it's at: metabolic changes in tumors. Breast Cancer Res 10: 202, 2008.